Trusted Resource for Clinical Trials, Protocols & Progress
SDV documentation refers to the section within the MVR where the CRA describes the extent of SDV performed during a site visit, the findings, any discrepancies noted, resolution status, and comments on overall data quality. It serves as a traceable record for sponsors, QA teams, and regulatory auditors.
Click to read the full article.
Without standardized procedures, CRAs may perform SDV inconsistently, leading to audit risks, missed data discrepancies, or non-compliance. Regulators such as USFDA and CDSCO expect sponsors to document how data is verified and to have procedures that ensure subject safety and data integrity.
Click to read the full article.
A risk-based approach to SDV involves prioritizing the verification of data that is critical to subject safety and primary endpoints. Instead of reviewing all data points equally, Clinical Research Associates (CRAs) focus on the areas that have the highest potential to affect trial outcomes or regulatory approval.
Click to read the full article.
According to USFDA and EMA guidance on risk-based monitoring, SDV is performed on critical data points such as primary endpoints and serious adverse events (SAEs). SDR is often used to verify overall compliance, protocol deviations, and source completeness. Sponsors may define these requirements in the Monitoring Plan and risk assessments.
Click to read the full article.
SDV is the process of comparing data recorded in the trial database to the original source data — such as patient charts, lab reports, or signed informed consent forms. As per USFDA and EMA guidance, SDV is a critical activity that supports the integrity, reliability, and credibility of clinical trial data.
Click to read the full article.
The objective of an RMV is to confirm subject safety, data accuracy, and protocol compliance. CRAs act on behalf of sponsors and regulators like the EMA and USFDA, identifying gaps and deviations that may compromise trial validity or regulatory approval. Addressing RMV findings quickly ensures site quality and builds sponsor trust.
Click to read the full article.
Miscommunication during monitoring visits can result in delayed responses to queries, unresolved deviations, and non-compliance with sponsor expectations. Strong CRA–site communication fosters trust, increases protocol adherence, and prepares the site for audits and inspections from authorities like USFDA or MHRA.
Click to read the full article.
A CTMS is a centralized software tool used to manage operational aspects of clinical trials. It supports planning and documentation of monitoring visits, investigator site communications, subject enrollment metrics, and compliance logs. CTMS platforms serve as a bridge between clinical sites, monitors, and sponsors.
Click to read the full article.
Proper preparation can prevent findings, minimize delays, and build confidence with the sponsor. It demonstrates your site’s commitment to quality, subject safety, and data integrity. Regulatory agencies like USFDA and Health Canada often examine site readiness through CRA monitoring reports.
Click to read the full article.
Documentation ensures that every observation and decision made during an RMV is traceable and verifiable. Regulatory agencies like the USFDA and EMA emphasize clear, contemporaneous, and accurate monitoring records in accordance with ICH E6(R2) guidelines.
Click to read the full article.
